Impact of the Treatment of Serenoa repens, Solanum lycopersicum, Lycopene and Bromelain in Combination with Alfuzosin for Benign Prostatic Hyperplasia. Results from a Match-Paired Comparison Analysis

Background: Phytotherapeutic agents aroused an increasing interest either as alternative or in addition to conventional therapy in the management of BPH. The aim of the article was to evaluate the clinical and functional changes after add-on treatment with Serenoa repens associated with Solanum lycopersicum, lycopene and bromelain in patients with BPH presenting with mild to moderate LUTS and previously treated only with Alfuzosin over a 6–12 months period. Materials and methods: Between January and July 2019, patients with symptomatic BPH already on treatment with Alfuzosin (Al) 10 mg for at least 6–12-month were enrolled at three academic referral centres, included in a prospective treatment group, and managed with a combination treatment of Al and 6-month daily oral single-tablet supplementation of Serenoa repens and Solanum lycopersicum + lycopene + bromelain (SeR + SL + Ly + Br). A retrospective control group with comparable baseline characteristics was obtained by performing a propensity score matching from a database of 434 patients managed with Alfuzosin 10 mg/day only over a 6–12 months period between March 2015 and December 2018. IPSS, QoL questionnaires, voiding diary assessment, postvoid residual volume (PVR), maximal (Qmax) and average (Qave) urinary flow rates were evaluated at baseline in the treatment group at the moment of patient accrual, in the control group after 6-month of treatment with alfuzosin, and thereafter at 3 and 6 months in both groups. Results: Overall, 250 patients entered the study (n = 125 treatment group; n = 125 control group). Total IPSS score significantly decreased at 6-month assessment from baseline in the treatment vs control group (17 [IQR: 12–20] vs 12 [IQR: 9–14], p = 0.02) with a significative storage symptoms improvement detected both at 3- (p = 0.03) and 6-month evaluation (p = 0.001). PVR significantly improved at each follow-up visit with the most relevant reduction at 6-month assessment (125 cc vs. 102 cc; p = 0.02). Moreover, a significative improvement in LUTS-related quality of life (QoL) was recorded at 3- and 6-month assessment with a median decrease of −1 and −2 (p = 0.05 and p = 0.001 respectively) from baseline. Conclusions: Combination treatment with AB and SeR + SL + Ly + Br led to meaningful improvements in LUTS severity compared to AB as monotherapy, after a 6-month treatment period in men with mild to moderate LUTS/BPH.

Download Full-text

Synergistic Effects of Quercetin-modified Silicone Gel Sheet in Scar Treatment

Journal of Burn Care & Research ◽

10.1093/jbcr/irab100 ◽

2021 ◽

Author(s):

Jian Jin ◽

Tao Tang ◽

Hao Zhou ◽

Xu-Dong Hong ◽

Hao Fan ◽

...

Keyword(s):

Treatment Group ◽

Combination Treatment ◽

Control Group ◽

Type I ◽

Blank Control Group ◽

Combination Treatment Group ◽

Silicone Gel ◽

Scar Treatment ◽

Silicone Gel Sheet ◽

Dressing Change

Abstract Both silicone gel and quercetin are effective in scar treatment but have different action mechanisms. Quercetin is mainly applied in the gel form and can lead to poor adhesion of silicone gel sheet; therefore, they cannot be combined in clinical use. In this study, a silicone gel sheet that releases quercetin in a sustained manner for 48 hours was successfully developed. Four round scars (Ø: 1 cm) were made in the ears of New-Zealand albino rabbits (n=10). After scar healing, the rabbits were divided into four groups: blank control group with no treatment, silicone gel sheet group with dressing change every 2 days, quercetin group with dressing change 3 times daily, and combination treatment group with dressing change every 2 days. Scar assessment was performed 3 months later. Transepidermal water loss showed no difference between the combination treatment group and the silicone gel sheet group, but was lower than that in the quercetin group and the blank control group. Immunohistochemistry of CD 31 and proliferating cell nuclear antigen showed the following results: combination treatment group < silicone gel sheet group = quercetin group < blank control group. Polymerase chain reaction results showed that the expression of type-I and type-III collagen in the combination treatment group and the quercetin group was significantly lower than that in the other two groups. Thus, quercetin-modified silicone gel sheet combines the advantages of the two treatments and is more effective at inhibiting cell proliferation in scar tissue than either of the two treatments alone.

Download Full-text

Pulsed Electromagnetic Field Affects the Development of Postmenopausal Osteoporotic Women with Vertebral Fractures

BioMed Research International ◽

10.1155/2021/4650057 ◽

2021 ◽

Vol 2021 ◽

pp. 1-9

Author(s):

Wei Liu ◽

Xiao Jin ◽

Zhiqiang Guan ◽

Qiyun Zhou

Keyword(s):

Electromagnetic Field ◽

Treatment Group ◽

Bone Loss ◽

Vertebral Fractures ◽

Bone Microstructure ◽

Control Group ◽

Pulsed Electromagnetic Field ◽

Related Quality ◽

Health Related ◽

Pulsed Electromagnetic

Background. Postoperative pain, dysfunction, and significant bone loss may occur after vertebral fractures, which will lead to the occurrence of refractures and shorten the survival time, so postoperative rehabilitation is very important. Pulsed electromagnetic field therapy is noninvasive, pain-relieving, and beneficial to reduce bone loss and is an important treatment for patients to recover after surgery. Therefore, this study analyzed the effect of postmenopausal women’s vertebral fracture rehabilitation after pulsed electromagnetic field treatment. Method. This study uses a randomized controlled study, respectively, in the pulsed electromagnetic field treatment group (40 cases) and the control group (42 cases), respectively. We studied the results of health-related quality of life scores (HRQOL), back pain, body function, hip bone density, bone microstructure of tibia, and radius after 1 month and 3 months after surgery. Results. Compared with the control group, the pulsed electromagnetic field treatment group (PEMF) can improve significantly the psychological score, 6-minute walk test, and Chair Sit-and-Reach one month after the operation. And at 3 months after surgery, the pulsed electromagnetic field treatment group can improve significantly in health-related quality of life scores (HRQOL), back pain, and body function. Regarding the effect of changes in bone mass, compared with the control group, pulsed electromagnetic field treatment had no significant effect on changes in hip bone density. As a result of changes in bone microstructure, pulsed electromagnetic field treatment can significantly improve the bone microstructure of the radius and tibia three months after vertebral fractures. Conclusion. Pulsed electromagnetic field therapy has positive significance for improving pain, body functional changes, and bone loss after vertebral fracture surgery.

Download Full-text

Effects of upper cervical translatoric mobilization on headache, quality of life, cervical mobility and pressure pain threshold in patients with cervicogenic headache: A randomized controlled trial.

10.21203/rs.3.rs-21657/v1 ◽

2020 ◽

Author(s):

Miguel Malo-Urriés ◽

José Miguel Tricás-Moreno ◽

Elena Estébanez-de-Miguel ◽

Elena Bueno-Gracia ◽

Pablo Fanlo-Mazas ◽

...

Keyword(s):

Quality Of Life ◽

Treatment Group ◽

Pain Threshold ◽

Pressure Pain Threshold ◽

Cervicogenic Headache ◽

Control Group ◽

Pressure Pain ◽

Upper Cervical ◽

Related Quality

Abstract Objective The purpose of this study was to evaluate the effects of upper cervical translatoric spinal mobilization (UC-TSM) on headache, quality of life, cervical mobility and pressure pain threshold in subjects with cervicogenic headache (CEH). Methods Eighty-two volunteers (41.5 ± 15.3 years; 20 males and 62 females) with CEH participated in the study and were randomly assigned to control or treatment group. The treatment group received 3 sessions of UC-TSM and the control group remained the same sessions, in the same position and time but received no treatment. Primary outcomes were Headache Impact Test for headache-related quality of life and flexion-rotation test for upper cervical mobility. Secondary outcomes included intensity, frequency and duration of headache, general cervical mobility and pressure pain thresholds over cervical spine. They were measured at baseline, at the end of the treatment and one month after the intervention. Results UC-TSM group increased significantly headache-related quality of life (p < .001; d = .857). Headache intensity, frequency and duration improved in UC-TSM group (p = .000-.013), in contrast to control group which did not obtain significant changes (p = .234-.965). UC-TSM group presented significant increases in upper cervical mobility (p < .001). Between-group effect sizes were considered large at T1 (d = 0.90–1.21) and moderate to large at T2 (d = 0.78–1.17). Conclusions Three sessions of UC-TSM increased headache-related quality of life and upper cervical mobility in subjects with CEH. Intensity, duration and frequency of headache, cervical mobility and PPT also improved. Further research considering the limitations of the present clinical trial is required to confirm this tendency.

Download Full-text

Herbal MedicineCordyceps sinensisImproves Health-Related Quality of Life in Moderate-to-Severe Asthma

Evidence-based Complementary and Alternative Medicine ◽

10.1155/2016/6134593 ◽

2016 ◽

Vol 2016 ◽

pp. 1-8 ◽

Cited By ~ 6

Author(s):

Ningqun Wang ◽

Jie Li ◽

Xiaobo Huang ◽

Wenqiang Chen ◽

Yujing Chen

Keyword(s):

Quality Of Life ◽

Treatment Group ◽

Lung Function ◽

Severe Asthma ◽

Cordyceps Sinensis ◽

Control Group ◽

Health Related Quality ◽

Related Quality ◽

Health Related

Moderate-to-severe asthma has a substantial impact on the health-related quality of life (HR-QOL) of the patients.Cordyceps sinensisis a traditional Chinese medicine that is evaluated clinically for the treatment of many diseases, such as chronic allograft nephropathy, diabetic kidney disease, and lung fibrosis. In order to investigate the effects ofCordyceps sinensison patients with moderate-to-severe persistent asthma, 120 subjects were randomized to receive Corbin capsule containingCordyceps sinensisfor 3 months (treatment group,n=60), whereas the control group (n=60) did not receive treatment with Corbin capsule. Inhaled corticosteroid and as-neededβ-agonists were used in the treatment of both groups. HR-QOL was measured with the Juniper’s Asthma Quality of Life Questionnaire (AQLQ). The incidence of asthma exacerbation, pulmonary function testing, and serum measurements of inflammatory mediators were also evaluated. The results showed that the treatment group indicated a significant increase in AQLQ scores and lung function compared with the control group. The expression levels of the inflammation markers IgE, ICAM-1, IL-4, and MMP-9 in the serum were decreased and IgG increased in the treatment group compared with the control group. Therefore, the conclusion was reached that a formulation ofCordyceps sinensisimproved the HR-QOL, asthma symptoms, lung function, and inflammatory profile of the patients with moderate-to-severe asthma. This trial is registered withChiCTR-IPC-16008730.

Download Full-text

Feasibility Trial of an eHealth Intervention for Health-Related Quality of Life: Implications for Managing Patients with Chronic Pain During the COVID-19 Pandemic

Healthcare ◽

10.3390/healthcare8040381 ◽

2020 ◽

Vol 8 (4) ◽

pp. 381

Author(s):

John C. Licciardone ◽

Vishruti Pandya

Keyword(s):

Treatment Group ◽

Self Management ◽

Control Group ◽

Low Back ◽

Wait List Control ◽

Cluster Score ◽

Related Quality ◽

Health Related ◽

Ehealth Intervention

Purpose: This study was conducted to determine the feasibility of providing an eHealth intervention for health-related quality of life (HRQOL) to facilitate patient self-management. Methods: A randomized controlled trial was conducted from 2019–2020 within the Pain Registry for Epidemiological, Clinical, and Interventional Studies and Innovation. Eligible patients included those with chronic low back pain and a SPADE (sleep disturbance, pain interference with activities, anxiety, depression, and low energy/fatigue) cluster score ≥ 55 based on the relevant scales from the Patient-Reported Outcomes Measurement Information System instrument with 29 items (PROMIS-29). Patients were randomized to the eHealth treatment group, which received a tailored HRQOL report and interpretation guide, or to a wait-list control group. The primary outcome was change in the SPADE cluster score, including its five component scales, over 3 months. Secondary outcomes were changes in low back pain intensity and back-related disability. Treatment effects were measured using the standardized mean difference (SMD) in change scores between groups. The eHealth intervention was also assessed by a survey of the experimental treatment group 1 month following randomization. Results: A total of 102 patients were randomized, including 52 in the eHealth treatment group and 50 in the wait-list control group, and 100 (98%) completed the trial. A majority of patients agreed that the HRQOL report was easy to understand (86%), provided new information (79%), and took actions to read or learn more about self-management approaches to improve their HRQOL (77%). Although the eHealth intervention met the criteria for a small treatment effect in improving the overall SPADE cluster score (SMD = 0.24; p= 0.23) and anxiety (SMD = 0.24; p = 0.23), and for a small-to-medium treatment effect in improving depression (SMD = 0.37; p = 0.06) and back-related disability (SMD = 0.36; p = 0.07), none of these results achieved statistical significance because of limited sample size. Conclusion: Given the feasibility of rapid online deployment, low cost, and low risk of adverse events, this eHealth intervention for HRQOL may be useful for patients with chronic pain during the COVID-19 pandemic.

Download Full-text

Combination treatment of vildagliptin and bay leaf (Syzygium polyanthum) extract increased pancreatic beta cells number but have no effect toward glycated albumin levels in diabetic male Wistar rats (Rattus norvegicus)

IJAAM (Indonesian Journal of Anti-Aging Medicine) ◽

10.36675/ijaam.v3i2.43 ◽

2019 ◽

Vol 3 (2) ◽

pp. 33

Author(s):

Meiyati Panambunan ◽

Wimpie Pangkahila ◽

Anak Agung Gede Budhiarta

Keyword(s):

Treatment Group ◽

Beta Cells ◽

Combination Treatment ◽

Rattus Norvegicus ◽

Pancreatic Beta Cells ◽

Wistar Rats ◽

Glycated Albumin ◽

Field Of View ◽

Control Group ◽

Male Wistar Rats

Introduction: Diabetes mellitus is a complex and progressive disease which often lead to several debilitating complications that partly caused by by free radicals which can be overcome with antioxidants. Bay leaves contain essential oils, tannins, flavonoids and terpenoids which have considerable antioxidant properties. Therefore, this study aims to determine the effect combination treatment of vildagliptin and bay leaf (Syzygium polyanthum) extract toward pancreatic beta cells density and glycated albumin levels in diabetic male Wistar rats (Rattus norvegicus). Methods: An experimental posttest only control group study was conducted using 36 albino male rats, aged 2-3 months, weighing 180-200 grams. The rats were divided into 2 groups (n= 18) with control group treated with 1.8mg/200g body weight vildagliptin and 2cc placebo (aquabidest) while the treatment group received 1.8mg/200g BW vildagliptin and 250 mg/200g BW bay leaves extract. All treatment lasted for 21 days. Results: The results showed that pancreatic beta cell counts in the treatment group was significantly higher than the control group (109.07 ± 20.47 cells/field of view vs 90.87 ± 13.91 cells/field of view; p<0.01). However, the levels of Glycated albumin between two groups were not significantly different (treatment vs control: 17.33 ± 4.51 vs 20.18 ± 4.57; p=0.068). Conclusion: This study suggested that combination treatment of vildagliptin and bay leaf extract increased pancreatic beta cells but did not reduce glycated albumin levels in diabetic male Wistar rats.

Download Full-text

Hirudo Lyophilized Powder Ameliorates Renal Injury in Diabetic Rats by Suppressing Oxidative Stress and Inflammation

Evidence-based Complementary and Alternative Medicine ◽

10.1155/2021/6657673 ◽

2021 ◽

Vol 2021 ◽

pp. 1-12

Author(s):

Fan Yang ◽

Yachun Li ◽

Shuai Guo ◽

Yongmei Pan ◽

Cuihuan Yan ◽

...

Keyword(s):

Oxidative Stress ◽

Treatment Group ◽

Microvascular Complications ◽

Renal Tissue ◽

Diabetic Rats ◽

Diabetic Group ◽

Control Group ◽

Functional Changes ◽

Diabetic Model ◽

Group 2

As diabetic nephropathy (DN) is one of the most common and destructive microvascular complications of diabetes mellitus, the goal of this study, therefore, was to investigate the renal protective effect and latent mechanisms of Hirudo lyophilized powder on diabetic rats. In this study, all rats were randomly assigned into the control group and diabetic group. The rats of diabetic group were injected with low-dose STZ (35 mg/kg) intraperitoneal plus high-fat diet to induce diabetes. Then, the successful diabetic model rats were weighed and randomly assigned into four groups: (1) diabetic model group (DM group); (2) Hirudo lyophilized powder 0.3 g/kg treatment group (SL group); (3) Hirudo lyophilized powder 0.6 g/kg treatment group (SM group); (4) Hirudo lyophilized powder 1.2 g/kg treatment group (SH group). Their fasting blood glucoses (FBG) were measured every 4 weeks. After treatment with Hirudo lyophilized powder at a corresponding dose once a day for 16 weeks, their metabolic and biochemical as well as oxidative stress parameters were tested, and the kidney weight (KW)/body weight (BW) was calculated. The renal tissues were used for histological, mRNA, and protein expression analysis. The results showed that Hirudo lyophilized powder could protect against the structural damages and functional changes of diabetic renal tissue by inhibiting oxidative stress, inflammation, and fibrosis. Furthermore, it was found in the further research that inhibiting the NOX4 expression and JAK2/STAT1/STAT3 pathway activation might be the underlying mechanisms. Collectively, Hirudo lyophilized powder might be a promising therapeutic agent for the treatment of DN.

Download Full-text

Comparative results of the use of transurethral resection and enucleation of the prostate in the treatment of patients with large-sized benign prostatic hyperplasia

World Ecology Journal ◽

10.25726/nm.2019.38.86.006 ◽

2018 ◽

pp. 50-59

Author(s):

Д.В. Торбик

Keyword(s):

Benign Prostatic Hyperplasia ◽

Treatment Group ◽

Transurethral Resection ◽

Clinical Results ◽

Prostatic Hyperplasia ◽

Average Score ◽

Control Group ◽

Urinary Flow ◽

Endoscopic Techniques ◽

Comparative Results

В представленном исследовании анализируются среднесрочные клинические результаты внедрения биполярной техники выполнения трансуретральной резекции и энуклеации в лечении доброкачественной гиперплазии предстательной железы (ДГПЖ) объемом более 80 см3. В исследование включено 84 пациента (основная группа), оперированных методом трансуретральной энуклеации предстательной железы, и 112 пациентов – методом биполярной трансуретральной резекции предстательной железы (контрольная группа). При применении исследуемых эндоскопических методов средний срок послеоперационной катетеризации составил 1,3 суток в основной группе и 1,4 дня в группе контроля, интра- и послеоперационные осложнения (кровотечение, инфекционно-воспалительные осложнения) были единичными, причем меньшая частота встречалась в основной группе. Через 6 месяцев после операции скорость потока мочи возросла на 13,9 мл/с в основной группе и на 10,9 мл/с в группе контроля, средний балл по шкале IPSS в итоге составил 3,2±0,2 балла и 4,1±0,1 балла в основной и контрольных группах соответственно (p<0,05). Полученные результаты в основной группе можно связать с большей радикальностью методики трансуретральной энуклеации простаты (ТУЭБ), объем резидуальной ткани узла в этой группе составил 5,6±0,7 см3 против 14,8±3,2 см3 в группе контроля (p<0,05). Таким образом, метод ТУЭБ может быть рекомендован к освоению врачам-урологам специализированных стационаров, как способ оперативного лечения ДГПЖ крупных размеров. In the present study, the mid-term clinical results of the introduction of the bipolar technique of performing transurethral resection and enucleation in the treatment of benign prostatic hyperplasia (BPH) of more than 80 cm3 are analyzed. The study involved 84 patients who underwent transurethral enucleation of the prostate (treatment group) and 112 patients – bipolar transurethral resection of the prostate (control group). In applying the endoscopic techniques under study, the mean duration of postoperative catheterization was 1.3 days in the treatment group and 1.4 days in the control group; intra- and postoperative complications (bleeding, infectious and inflammatory complications) were incidental with lower occurrence in the treatment group. In 6 months after surgery, the urinary flow rate increased by 13.9 mL/s in the treatment group and by 10.9 mL/s in the control group, the average score on the IPSS scale was 3.2 ± 0.2 points and 4.1 ± 0.1 points in the main and control groups, respectively (p <0.05). The results obtained in the main group can be attributed to the more radical methods of transurethral enucleation of the prostate (TEOB), the volume of residual tissue in this group was 5.6 ± 0.7 cm3 against 14.8 ± 3.2 cm3 in the control group (p<0,05). Thus, the TEOB method can be recommended for mastering by urologists of specialized hospitals as a method of surgical treatment of large-size BPH.

Download Full-text

Effect of thermobalancing therapy on chronic prostatitis and chronic pelvic pain syndrome

Journal of Clinical Urology ◽

10.1177/2051415816671036 ◽

2016 ◽

Vol 10 (4) ◽

pp. 347-354 ◽

Cited By ~ 8

Author(s):

Simon Allen ◽

Ivan G Aghajanyan

Keyword(s):

Treatment Group ◽

Pelvic Pain ◽

Chronic Prostatitis ◽

Chronic Pelvic Pain ◽

Chronic Pelvic Pain Syndrome ◽

Pain Syndrome ◽

Pelvic Pain Syndrome ◽

Control Group ◽

Urinary Flow ◽

Significant Difference

Background: Type-III chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) is the most common type of prostatitis. Patients and methods: We ascertained the effect of ‘thermobalancing’ therapy (TT; using Dr Allen’s therapeutic device (DATD)) on CP/CPPS. We measured National Institute of Health Chronic Prostatitis Symptom Index (NIH-CPSI) scores, prostatic volume (PV), and maximum urinary flow rate (Qmax) in one group of 45 patients who underwent TT and a control group that did not have TT, and compared these parameters between groups. Results: Baseline evaluation (pretreatment) of both groups showed no significant difference with regard to age, NIH-CPSI score, PV or Qmax. Pain score decreased in both groups but, in the treatment group, the difference between scores was considerably higher (8.72:1) than that of the non-treatment group. TT decreased quality of life (QoL) significantly whereas, in the control group, it decreased QoL slightly. TT reduced PV significantly whereas, in the control group, PV increased. TT increased Qmax significantly in CP/CPPS patients whereas, in the control group, TT did not elicit a significant change in Qmax. Conclusions: Six-month TT with DATD: (a) reduces CP/CPPS symptoms and improves QoL; (b) reduces PV; (c) increases Qmax. TT could be effective treatment for CP/CPPS.

Download Full-text

ACCEPT®: A Complementary Anthroposophical Program for the Palliative Treatment of Lung Cancer – Rationale and a Randomized Feasibility Study

Complementary Medicine Research ◽

10.1159/000516820 ◽

2021 ◽

pp. 1-8

Author(s):

Silke Schibel ◽

Marie Steinert ◽

Harald Matthes ◽

Christian Grah

Keyword(s):

Quality Of Life ◽

Lung Cancer ◽

Treatment Group ◽

Cancer Patients ◽

Control Group ◽

Health Related Quality ◽

Lung Cancer Patients ◽

Related Quality ◽

Health Related

Background: Lung cancer is the oncological disease with the highest mortality worldwide. Health-related quality of life is severely compromised in the majority of patients. While the efficacy of early palliative psychosocial therapy has been demonstrated in several recent studies, appropriate therapy modules could so far not be integrated into daily practice of care. Therefore, an additive multimodal treatment concept for oncological centers was drafted: the Additive anthroposophic integrative medicine Cancer Concept of Early supportive or Palliative lung cancer Treatment (ACCEPT®). Patients and Methods: The first module consisted of a 3-month health education program, the second module was a concept of psychosocial interventions, and the third module was a supervised home training program. Between 2017 and 2018, 20 lung cancer patients (UICC IIIB/IV) were included and randomly assigned to treatment (n = 10) or a waiting control group (n = 10). The treatment group started ACCEPT® for 3 months immediately after diagnosis and received also standard oncological care (SOC) while the waiting control group received SOC only for 3 months, followed by ACCEPT® after this period. Health-related quality of life, disease management, disease-specific symptoms, and feasibility of the ACCEPT® were monitored at 4 time points. Results: 7 out of 10 patients in the treatment group (3 dropped out) and 6 out of 10 in the waiting control group (4 died during the intervention) completed treatment. Discussion/Conclusion: Lung cancer patients with high symptom load may benefit from ACCEPT®. The feasibility of this adjunctive therapy was demonstrated. The combination of SOC and ACCEPT® is feasible and applicable to a heterogeneous patient group and should be further evaluated with respect to efficacy and dosing.

Download Full-text